- Home
- OBT vs ERAS Comparison
OBT vs ERAS Comparison
Compare OBT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBT | ERAS |
|---|---|---|
| Founded | 1892 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.1M | 927.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OBT | ERAS |
|---|---|---|
| Price | $28.79 | $3.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $31.00 | $3.71 |
| AVG Volume (30 Days) | 23.2K | ★ 2.0M |
| Earning Date | 10-29-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 18.38 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | ★ $115,418,000.00 | N/A |
| Revenue This Year | $19.86 | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | $9.47 | ★ N/A |
| Revenue Growth | ★ 17.75 | N/A |
| 52 Week Low | $20.97 | $1.01 |
| 52 Week High | $30.40 | $3.62 |
Technical Indicators
Market Signals| Indicator | OBT | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 71.02 | 71.90 |
| Support Level | $27.00 | $3.15 |
| Resistance Level | $29.31 | $3.48 |
| Average True Range (ATR) | 0.77 | 0.22 |
| MACD | 0.15 | 0.03 |
| Stochastic Oscillator | 81.93 | 99.81 |
Price Performance
Historical ComparisonAbout OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.